A stable ferric iron complex with maltol that facilitates intestinal iron delivery and absorption. Following absorption, iron enters normal transferrin-mediated transport and is incorporated into haemoglobin and iron stores.
Indications / reported uses
Treatment of iron-deficiency anaemia in adults with chronic kidney disease not on dialysis where authorised
Treatment of iron deficiency in adults and eligible paediatric patients aged 10 years and older under the US ACCRUFER indication; follow product-specific haemoglobin and iron-index monitoring
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Ferric Maltol Environmental Risk Assessment (ERA) (the Ferric Maltol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.